Cordis Downplays Drug-Eluting Stents As Future Growth Driver
This article was originally published in The Gray Sheet
Executive Summary
A slowdown in drug-eluting stent sales growth is forcing Johnson & Johnson's Cordis unit to shift its attention to other segments as future growth drivers